The ability of silk fibroin to self-assemble into stable, tunable, and biocompatible three-dimensional structures has opened an entirely new landscape in regenerative medicine over the past several years. Its application in the fabrication of microcapsules designed for cellular encapsulation is now one of the most promising approaches to resolving one of the central challenges in stem cell therapy: ensuring post-transplant cell survival and maintaining precise control over the cellular microenvironment.
Microcapsule architecture and porosity control
Fibroin microcapsules are produced through a range of technological platforms, including droplet microfluidics, interfacial coacervation, and sacrificial templating on calcium carbonate particles. Each method allows precise modulation of critical parameters such as capsule diameter (typically in the 100–500 µm range), wall thickness, and pore size distribution. The porous architecture of fibroin is particularly significant from a functional standpoint: pores with diameters between 5 and 20 nm allow the free diffusion of small molecules such as glucose, oxygen, and growth factors, while impeding the passage of IgG antibodies (hydrodynamic diameter ~10 nm in extended conformation) and cytotoxic immune cells, effectively establishing a semi-selective immunoprotective barrier.
The mechanical behavior of the capsules can be optimized through β-sheet crystallization induced by methanol vapor exposure, or through enzymatic crosslinking with horseradish peroxidase (HRP) in the presence of H?O?. The latter approach yields hydrogels with elastic moduli ranging from 1 to 100 kPa — a range critical for recapitulating the mechanical properties of the target tissue and for directing stem cell differentiation via mechanotransduction.
Encapsulation of mesenchymal stem cells and iPSCs
Among the cell populations most extensively studied in combination with fibroin microcapsules are mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). MSCs benefit substantially from encapsulation because the fibroin matrix partially mimics the architecture of the bone marrow extracellular matrix, significantly reducing the post-transplant viability loss that in conventional direct injection protocols can exceed 90% within the first 24 hours.
Studies by Zhang et al. (Biomaterials, 2022) have documented that MSCs encapsulated within crosslinked fibroin hydrogels maintain a paracrine secretory profile — in terms of VEGF, HGF, and IL-6 — significantly higher than that of non-encapsulated cells implanted at the same site. This finding is clinically relevant because MSCs exert their therapeutic effect predominantly through paracrine mechanisms rather than through direct tissue integration; preserving cellular viability and secretory function within a biocompatible capsule is therefore equivalent to preserving the mechanism of action that matters most in a clinical context.
For iPSCs, the challenge is more complex: these cells require highly specific culture conditions and tend to form aggregates (embryoid bodies) that, when uncontrolled, give rise to heterogeneous differentiation outcomes. Fibroin microcapsules are able to limit the size of the three-dimensional spheroids that iPSCs form within their interior — through the physical confinement of the capsule cavity — thereby reducing hypoxia-driven central necrosis in embryoid bodies exceeding 400 µm in diameter. At the same time, the ability to functionalize the internal surface of the capsules with adhesion peptides such as RGD (arginine-glycine-aspartate) or laminin-derived sequences makes it possible to guide differentiation toward specific lineages, including neural, cardiomyocytic, and hepatocytic fates.
Immunomodulation and immunoisolation strategies
One of the most clinically significant aspects of fibroin microcapsules is their capacity to modulate the host immune response. Unlike alginate hydrogels — the material historically most used in cellular immunoisolation — silk fibroin degrades slowly in vivo without releasing significant pro-inflammatory fragments. Degradation occurs primarily through hydrolysis and enzymatic proteolysis (serine proteases, matrix metalloproteinases), with kinetics that can be tuned by adjusting the degree of β-sheet crystallinity: a highly crystalline structure can maintain structural integrity for several months in vivo, while more amorphous formulations degrade within a few weeks.
The immune response to fibroin microcapsules implanted subcutaneously or intraperitoneally is characterized by a low-grade foreign body reaction, with predominantly M2 rather than M1 macrophage infiltration during the first weeks post-implantation. This anti-inflammatory macrophage phenotype is favorable for long-term cell survival and for peripheral vascularization of the capsule. Several research groups have also incorporated local immunosuppressive molecules into the fibroin matrix — such as dexamethasone or anti-CD154 antibodies — exploiting the porous structure as a controlled-release system, thereby achieving a dual function: cellular container and pharmacological reservoir.
Applications in oncology and regenerative medicine
In oncology, fibroin microcapsules containing stem cells engineered to express prodrug-activating enzymes (the GDEPT approach — gene-directed enzyme prodrug therapy) have been proposed as a platform for locoregional therapy of solid tumors. The encapsulated cells are implanted in proximity to the tumor mass and activated through systemic administration of a non-toxic prodrug which, converted locally by the enzyme expressed by the encapsulated cells, generates a cytotoxic metabolite in situ. The fibroin capsule protects the therapeutic cells from the immune system and prolongs their survival within the typically hostile tumor microenvironment.
In regenerative medicine, the most advanced applications concern the treatment of type 1 diabetes, involving the encapsulation of pancreatic β cells derived from iPSCs or from donor islets. Several preclinical protocols in murine and non-human primate models have demonstrated the ability of these capsules to restore normoglycemia for periods exceeding 90 days without systemic immunosuppression, with a glucose-dependent insulin response functionally equivalent to that of native islets. Phase I/II clinical trials currently underway are exploring composite fibroin-alginate formulations designed to combine the long-term biocompatibility of the former with the optimized selective permeability of the latter.
Open challenges and future directions
Despite these promising results, several unresolved challenges remain. Insufficient vascularization is still the primary limiting factor for long-term cell survival in capsules larger than 300 µm: the oxygen diffusion distance within non-vascularized tissue is approximately 150–200 µm, making necrosis of the capsule core nearly inevitable in the absence of pro-angiogenic strategies. The incorporation of factors such as VEGF165 or the co-encapsulation of endothelial cells offers a partial solution, but introduces additional regulatory and manufacturing complexity.
On the production side, standardizing fibroin microcapsule manufacturing to GMP (Good Manufacturing Practice) scale remains an open challenge, particularly with respect to controlling size distribution and ensuring reproducibility of the crosslinking degree across batches. Rheological characterization and ATR-mode FTIR spectroscopy represent the reference tools for material quality control, but their integration into inline production processes still requires substantial methodological development.
The convergence of biomaterial bioengineering and stem cell genetic engineering — through the introduction of synthetic transcriptional control systems (inducible genetic circuits) into encapsulated cells — opens particularly compelling prospects for precision therapy, in which the capsule functions not merely as a protective shell but as the interface module between a programmable cellular system and the host physiological environment.
